In this presentation, oncologic surgeon Giorgios C. Karakousis, MD, considers the reasons, parameters, morbidity, prognostic value and outcomes of patients receiving sentinel lymph node biopsy for melanoma, and reviews adjuvant and neoadjuvant (BRAF inhibitors, nivolumab, ipilimumab) therapies in stage III/IV resectable disease.